Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

GLP-1 weight loss drugs — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — work by suppressing appetite and delaying the rate at which your stomach empties.

Mounjaro and Zepbound are drugs known as tirzepatide. Mounjaro was approved in 2017 to treat Type 2 diabetes, while Zepbound was approved in more recent years to treat obesity. Like semaglutide ...

Mounjaro, which is the brand name for tirzepatide, is a drug that lowers blood sugar levels. It works by activating two receptors known as GLP-1 and GIP to increase the level of incretins ...

It was the first head-to-head comparison of the injectable GLP-1 medications semaglutide and tirzepatide, which are sold under the brand names Wegovy and Zepbound for weight loss. Roughly 750 ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change obesity treatment options in India and beyond. Listen to Story Tirzepatide led ...

“We can treat it kind of the same way we treated semaglutide and tirzepatide,” the active ingredients in Ozempic and Zepbound. Fritzler says Olympia plans to begin ramping up production this summe ...

Wegovy is approved for use in weight management. Another group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management.

With countless supplements flooding the market, many are turning their attention to a unique and evolving category: SARMs (Selective Androgen Receptor Modulators), peptides, injectables, and ...

How lab-tested SARMs such as RAD-140, LGD-4033, and MK-2866 compare in purity and reliability for research purposes Why research peptides like BPC-157 and TB-500 are frequently studied for their ...

(Alexander Quon/CBC News) SARM has called for funding to help clean up the increasing number of derelict and abandoned buildings in the province. "Many [RMs] struggle with limited funds ...

For a time, pharmacies were able to make compounded versions of drugs that had semaglutide or tirzepatide as the active ingredient because of a shortage. In December 2024, the FDA announced that ...